A detailed history of Rhumbline Advisers transactions in Adagene Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 8,965 shares of ADAG stock, worth $18,378. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,965
Previous 8,965 -0.0%
Holding current value
$18,378
Previous $27,000 29.63%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$1.15 - $1.6 $7,762 - $10,800
6,750 Added 304.74%
8,965 $13,000
Q2 2023

Aug 08, 2023

BUY
$1.17 - $1.76 $2,591 - $3,898
2,215 New
2,215 $3,000

Others Institutions Holding ADAG

About Adagene Inc.


  • Ticker ADAG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,423,200
  • Market Cap $89M
  • Description
  • Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...
More about ADAG
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.